Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
Identifieur interne : 001729 ( PubMed/Curation ); précédent : 001728; suivant : 001730Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
Auteurs : Jorge J. Castillo [États-Unis] ; Ramon Garcia-Sanz [Espagne] ; Evdoxia Hatjiharissi [Grèce] ; Robert A. Kyle [États-Unis] ; Xavier Leleu [France] ; Mary Mcmaster [États-Unis] ; Giampaolo Merlini [Italie] ; Monique C. Minnema [Pays-Bas] ; Enrica Morra [Italie] ; Roger G. Owen [Royaume-Uni] ; Stephanie Poulain [France] ; Marvin J. Stone [États-Unis] ; Constantine Tam [Australie] ; Marzia Varettoni [Italie] ; Meletios A. Dimopoulos [Grèce] ; Steven P. Treon [États-Unis] ; Efstathios Kastritis [Grèce]Source :
- British journal of haematology [ 1365-2141 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
Abstract
The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
DOI: 10.1111/bjh.14196
PubMed: 27378193
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001752
Links to Exploration step
pubmed:27378193Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.</title><author><name sortKey="Castillo, Jorge J" sort="Castillo, Jorge J" uniqKey="Castillo J" first="Jorge J" last="Castillo">Jorge J. Castillo</name><affiliation wicri:level="1"><nlm:affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jorgej_castillo@dfci.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Garcia Sanz, Ramon" sort="Garcia Sanz, Ramon" uniqKey="Garcia Sanz R" first="Ramon" last="Garcia-Sanz">Ramon Garcia-Sanz</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea></affiliation></author><author><name sortKey="Hatjiharissi, Evdoxia" sort="Hatjiharissi, Evdoxia" uniqKey="Hatjiharissi E" first="Evdoxia" last="Hatjiharissi">Evdoxia Hatjiharissi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki</wicri:regionArea></affiliation></author><author><name sortKey="Kyle, Robert A" sort="Kyle, Robert A" uniqKey="Kyle R" first="Robert A" last="Kyle">Robert A. Kyle</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation wicri:level="1"><nlm:affiliation>La Miletrie Hospital, CHU Poitiers, Poitiers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>La Miletrie Hospital, CHU Poitiers, Poitiers</wicri:regionArea></affiliation></author><author><name sortKey="Mcmaster, Mary" sort="Mcmaster, Mary" uniqKey="Mcmaster M" first="Mary" last="Mcmaster">Mary Mcmaster</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Merlini, Giampaolo" sort="Merlini, Giampaolo" uniqKey="Merlini G" first="Giampaolo" last="Merlini">Giampaolo Merlini</name><affiliation wicri:level="1"><nlm:affiliation>Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Minnema, Monique C" sort="Minnema, Monique C" uniqKey="Minnema M" first="Monique C" last="Minnema">Monique C. Minnema</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, UMC Utrecht Cancer Centre, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Haematology, UMC Utrecht Cancer Centre, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Morra, Enrica" sort="Morra, Enrica" uniqKey="Morra E" first="Enrica" last="Morra">Enrica Morra</name><affiliation wicri:level="1"><nlm:affiliation>Division of Haematology, Niguarda Ca' Granda Hospital, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Haematology, Niguarda Ca' Granda Hospital, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Owen, Roger G" sort="Owen, Roger G" uniqKey="Owen R" first="Roger G" last="Owen">Roger G. Owen</name><affiliation wicri:level="1"><nlm:affiliation>St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Poulain, Stephanie" sort="Poulain, Stephanie" uniqKey="Poulain S" first="Stephanie" last="Poulain">Stephanie Poulain</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes</wicri:regionArea></affiliation></author><author><name sortKey="Stone, Marvin J" sort="Stone, Marvin J" uniqKey="Stone M" first="Marvin J" last="Stone">Marvin J. Stone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Varettoni, Marzia" sort="Varettoni, Marzia" uniqKey="Varettoni M" first="Marzia" last="Varettoni">Marzia Varettoni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Treon, Steven P" sort="Treon, Steven P" uniqKey="Treon S" first="Steven P" last="Treon">Steven P. Treon</name><affiliation wicri:level="1"><nlm:affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27378193</idno><idno type="pmid">27378193</idno><idno type="doi">10.1111/bjh.14196</idno><idno type="wicri:Area/PubMed/Corpus">001752</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001752</idno><idno type="wicri:Area/PubMed/Curation">001729</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001729</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.</title><author><name sortKey="Castillo, Jorge J" sort="Castillo, Jorge J" uniqKey="Castillo J" first="Jorge J" last="Castillo">Jorge J. Castillo</name><affiliation wicri:level="1"><nlm:affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jorgej_castillo@dfci.harvard.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Garcia Sanz, Ramon" sort="Garcia Sanz, Ramon" uniqKey="Garcia Sanz R" first="Ramon" last="Garcia-Sanz">Ramon Garcia-Sanz</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Salamanca, Salamanca</wicri:regionArea></affiliation></author><author><name sortKey="Hatjiharissi, Evdoxia" sort="Hatjiharissi, Evdoxia" uniqKey="Hatjiharissi E" first="Evdoxia" last="Hatjiharissi">Evdoxia Hatjiharissi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki</wicri:regionArea></affiliation></author><author><name sortKey="Kyle, Robert A" sort="Kyle, Robert A" uniqKey="Kyle R" first="Robert A" last="Kyle">Robert A. Kyle</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Leleu, Xavier" sort="Leleu, Xavier" uniqKey="Leleu X" first="Xavier" last="Leleu">Xavier Leleu</name><affiliation wicri:level="1"><nlm:affiliation>La Miletrie Hospital, CHU Poitiers, Poitiers, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>La Miletrie Hospital, CHU Poitiers, Poitiers</wicri:regionArea></affiliation></author><author><name sortKey="Mcmaster, Mary" sort="Mcmaster, Mary" uniqKey="Mcmaster M" first="Mary" last="Mcmaster">Mary Mcmaster</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Merlini, Giampaolo" sort="Merlini, Giampaolo" uniqKey="Merlini G" first="Giampaolo" last="Merlini">Giampaolo Merlini</name><affiliation wicri:level="1"><nlm:affiliation>Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Minnema, Monique C" sort="Minnema, Monique C" uniqKey="Minnema M" first="Monique C" last="Minnema">Monique C. Minnema</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, UMC Utrecht Cancer Centre, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Haematology, UMC Utrecht Cancer Centre, Utrecht</wicri:regionArea></affiliation></author><author><name sortKey="Morra, Enrica" sort="Morra, Enrica" uniqKey="Morra E" first="Enrica" last="Morra">Enrica Morra</name><affiliation wicri:level="1"><nlm:affiliation>Division of Haematology, Niguarda Ca' Granda Hospital, Milano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Haematology, Niguarda Ca' Granda Hospital, Milano</wicri:regionArea></affiliation></author><author><name sortKey="Owen, Roger G" sort="Owen, Roger G" uniqKey="Owen R" first="Roger G" last="Owen">Roger G. Owen</name><affiliation wicri:level="1"><nlm:affiliation>St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds</wicri:regionArea></affiliation></author><author><name sortKey="Poulain, Stephanie" sort="Poulain, Stephanie" uniqKey="Poulain S" first="Stephanie" last="Poulain">Stephanie Poulain</name><affiliation wicri:level="1"><nlm:affiliation>Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes</wicri:regionArea></affiliation></author><author><name sortKey="Stone, Marvin J" sort="Stone, Marvin J" uniqKey="Stone M" first="Marvin J" last="Stone">Marvin J. Stone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX</wicri:regionArea></affiliation></author><author><name sortKey="Tam, Constantine" sort="Tam, Constantine" uniqKey="Tam C" first="Constantine" last="Tam">Constantine Tam</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Varettoni, Marzia" sort="Varettoni, Marzia" uniqKey="Varettoni M" first="Marzia" last="Varettoni">Marzia Varettoni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Treon, Steven P" sort="Treon, Steven P" uniqKey="Treon S" first="Steven P" last="Treon">Steven P. Treon</name><affiliation wicri:level="1"><nlm:affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens</wicri:regionArea></affiliation></author></analytic><series><title level="j">British journal of haematology</title><idno type="eISSN">1365-2141</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advisory Committees</term><term>Humans</term><term>London</term><term>Practice Guidelines as Topic</term><term>Waldenstrom Macroglobulinemia (diagnosis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Comités consultatifs</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Londres</term><term>Macroglobulinémie de Waldenström (diagnostic)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Waldenstrom Macroglobulinemia</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Macroglobulinémie de Waldenström</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Advisory Committees</term><term>Humans</term><term>London</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Comités consultatifs</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Londres</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27378193</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>24</Day></DateCreated><DateCompleted><Year>2017</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2141</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation></Journal><ArticleTitle>Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.</ArticleTitle><Pagination><MedlinePgn>77-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.14196</ELocationID><Abstract><AbstractText>The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.</AbstractText><CopyrightInformation>© 2016 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-9490-7532</Identifier><AffiliationInfo><Affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jorgej_castillo@dfci.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Sanz</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatjiharissi</LastName><ForeName>Evdoxia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Haematology, Theageneion Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyle</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Hematology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leleu</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>La Miletrie Hospital, CHU Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMaster</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlini</LastName><ForeName>Giampaolo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnema</LastName><ForeName>Monique C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Haematology, UMC Utrecht Cancer Centre, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morra</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Haematology, Niguarda Ca' Granda Hospital, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Roger G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulain</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service d'Hématologie-Immunologie-Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Marvin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Oncology, Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Constantine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Haematology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varettoni</LastName><ForeName>Marzia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>Meletios A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Treon</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastritis</LastName><ForeName>Efstathios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 CA999999</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):198-201</RefSource><PMID Version="1">23477936</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2006 Jun;20(6):1179-81</RefSource><PMID Version="1">16598310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Medicine (Baltimore). 2008 Mar;87(2):99-109</RefSource><PMID Version="1">18344807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2003 Apr;30(2):142-5</RefSource><PMID Version="1">12720124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Mar 8;119(10):2205-8</RefSource><PMID Version="1">22147890</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Mar 15;22(6):1480-8</RefSource><PMID Version="1">26490317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):433-7</RefSource><PMID Version="1">23084402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma. 2009 Mar;9(1):97-9</RefSource><PMID Version="1">19362986</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):224-8</RefSource><PMID Version="1">16421127</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma. 2009 Mar;9(1):110-2</RefSource><PMID Version="1">19362990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Apr 30;113(18):4163-70</RefSource><PMID Version="1">19196866</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 May 1;123(18):2791-6</RefSource><PMID Version="1">24553177</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2007 Jan;136(1):80-6</RefSource><PMID Version="1">17222197</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2015 Mar;262(3):666-73</RefSource><PMID Version="1">25549972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 May 1;17(9):3013-8</RefSource><PMID Version="1">21415221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 Jan;28(1):166-73</RefSource><PMID Version="1">23604227</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Amyloid. 2014 Dec;21(4):221-4</RefSource><PMID Version="1">25263598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Clin Pract Neurol. 2008 Oct;4(10):547-56</RefSource><PMID Version="1">18813229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2004 Dec 1;101(11):2593-8</RefSource><PMID Version="1">15493038</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2010 Mar;95(3):470-5</RefSource><PMID Version="1">19903677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Feb 15;101(4):1570-1</RefSource><PMID Version="1">12393502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Aug 30;367(9):826-33</RefSource><PMID Version="1">22931316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2015 Apr 2;125(14):2239-44</RefSource><PMID Version="1">25636337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hematol. 2015 Feb;90(2):100-4</RefSource><PMID Version="1">25349134</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2003 Apr;30(2):110-5</RefSource><PMID Version="1">12720118</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Amyloid. 2012 Jun;19 Suppl 1:11-3</RefSource><PMID Version="1">22551153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2016 Mar;172(5):709-15</RefSource><PMID Version="1">26686858</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Oct 18;120(16):3214-21</RefSource><PMID Version="1">22896002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Oncol. 2003 Apr;30(2):116-20</RefSource><PMID Version="1">12720119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2009 Jun;22(6):807-16</RefSource><PMID Version="1">19287458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Jun 26;123(26):4120-31</RefSource><PMID Version="1">24711662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Dec 3;114(24):4957-9</RefSource><PMID Version="1">19797517</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 2005 Sep;124(3):414-20</RefSource><PMID Version="1">16191510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 Aug;28(8):1698-704</RefSource><PMID Version="1">24509637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2012 Sep;60(3):487-91</RefSource><PMID Version="1">22721930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2013 Apr;98(4):649-54</RefSource><PMID Version="1">23065509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Jan 12;119(2):488-93</RefSource><PMID Version="1">22106346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2013 May 30;121(22):4504-11</RefSource><PMID Version="1">23532735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2015 Apr;169(1):81-9</RefSource><PMID Version="1">25521528</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2004 Oct;15(10):1481-3</RefSource><PMID Version="1">15367407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2015 Dec;100(12):1587-94</RefSource><PMID Version="1">26385211</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Aug 6;373(6):584-6</RefSource><PMID Version="1">26244327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2008 Mar;140(5):547-51</RefSource><PMID Version="1">18275432</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Aug;27(8):1722-8</RefSource><PMID Version="1">23446312</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2015 Aug 6;126(6):721-32</RefSource><PMID Version="1">26002963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):241-3</RefSource><PMID Version="1">23523274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):176-9</RefSource><PMID Version="1">21856554</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):160-3</RefSource><PMID Version="1">21454222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jan 10;27(2):250-5</RefSource><PMID Version="1">19064987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Apr 9;372(15):1430-40</RefSource><PMID Version="1">25853747</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Mar 13;123(11):1637-46</RefSource><PMID Version="1">24366360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2015 Jun;169(6):795-803</RefSource><PMID Version="1">25819228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2015 Mar 26;125(13):2174-5</RefSource><PMID Version="1">25814489</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Sep 17;114(12):2375-85</RefSource><PMID Version="1">19617573</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2014 Jun 19;123(25):3999-4000</RefSource><PMID Version="1">24948623</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D026683" MajorTopicYN="N">Advisory Committees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008258" MajorTopicYN="N">Waldenstrom Macroglobulinemia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bing-Neel syndrome</Keyword><Keyword MajorTopicYN="N">Waldenström macroglobulinaemia</Keyword><Keyword MajorTopicYN="N">amyloidosis</Keyword><Keyword MajorTopicYN="N">anaemia</Keyword><Keyword MajorTopicYN="N">hyperviscosity</Keyword><Keyword MajorTopicYN="N">neuropathy</Keyword></KeywordList><CoiStatement>JJC received honoraria from Celgene and Pharmacyclics, and research funding from Abbvie, Gilead, Millennium and Pharmacyclics. RGS received honoraria from Bristol-Myers Squibb, Janssen and Takeda and. EH received honoraria from Amgen, Gilead and Janssen. GM received honoraria from GlaxoSmithKline, Janssen and Millennium-Takeda. RGO received honoraria from Celgene, Janssen, Pharmacyclics and Roche, and research funding from Celgene. CT received honoraria and research funding from Janssen and Roche. MAD received honoraria from Amgen, Celgene, Janssen and Novartis. SPT received research funding and/or honoraria from Gilead, Janssen, Onyx and Pharmacyclics. EK received honoraria from Amgen, Janssen and Takeda and. RAK, XL, MM, MCM, EM, SP, MJS, MV have no conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27378193</ArticleId><ArticleId IdType="doi">10.1111/bjh.14196</ArticleId><ArticleId IdType="pmc">PMC5154335</ArticleId><ArticleId IdType="mid">NIHMS833369</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001729 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001729 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27378193
|texte= Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27378193" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |